- Home
- IMRX vs ARMP Comparison
IMRX vs ARMP Comparison
Compare IMRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- ARMP
- Stock Information
- Founded
- IMRX 2008
- ARMP N/A
- Country
- IMRX United States
- ARMP United States
- Employees
- IMRX N/A
- ARMP N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMRX Health Care
- ARMP Health Care
- Exchange
- IMRX Nasdaq
- ARMP Nasdaq
- Market Cap
- IMRX 52.2M
- ARMP 52.1M
- IPO Year
- IMRX 2021
- ARMP N/A
- Fundamental
- Price
- IMRX $1.87
- ARMP $1.94
- Analyst Decision
- IMRX Strong Buy
- ARMP Strong Buy
- Analyst Count
- IMRX 3
- ARMP 1
- Target Price
- IMRX $15.33
- ARMP $9.00
- AVG Volume (30 Days)
- IMRX 240.9K
- ARMP 624.1K
- Earning Date
- IMRX 05-05-2025
- ARMP 05-14-2025
- Dividend Yield
- IMRX N/A
- ARMP N/A
- EPS Growth
- IMRX N/A
- ARMP N/A
- EPS
- IMRX N/A
- ARMP N/A
- Revenue
- IMRX N/A
- ARMP $4,699,000.00
- Revenue This Year
- IMRX N/A
- ARMP $8.43
- Revenue Next Year
- IMRX N/A
- ARMP N/A
- P/E Ratio
- IMRX N/A
- ARMP N/A
- Revenue Growth
- IMRX N/A
- ARMP 14.24
- 52 Week Low
- IMRX $1.00
- ARMP $0.90
- 52 Week High
- IMRX $3.83
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- IMRX 68.56
- ARMP 56.46
- Support Level
- IMRX $1.58
- ARMP $1.90
- Resistance Level
- IMRX $1.85
- ARMP $2.20
- Average True Range (ATR)
- IMRX 0.15
- ARMP 0.33
- MACD
- IMRX 0.05
- ARMP 0.02
- Stochastic Oscillator
- IMRX 97.20
- ARMP 49.68
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.